Stay updated on NYX-2925 Efficacy & Safety in DPN Clinical Trial
Sign up to get notified when there's something new on the NYX-2925 Efficacy & Safety in DPN Clinical Trial page.

Latest updates to the NYX-2925 Efficacy & Safety in DPN Clinical Trial page
- Check5 days agoChange DetectedAdded a Locations section listing study sites across AZ, CA, CT, FL, GA, ID, IL, MO, NJ, NY, OH, TN, TX, and VA, and removed several state-specific location subsections and the HHS Vulnerability Disclosure.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check40 days agoChange DetectedThe banner about a lapse in government funding and related operating status was removed from the page. It previously directed users to cc.nih.gov and opm.gov for status updates.SummaryDifference0.3%

- Check55 days agoChange DetectedNo significant changes detected between the two screenshots; the page content and layout appear unchanged.SummaryDifference0.4%

- Check76 days agoChange DetectedAdded a prominent government funding notice and a new v3.2.0 version tag; removed the old v3.1.0 version tag.SummaryDifference3%

- Check90 days agoChange DetectedAdds v3.1.0 and removes several drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) while also removing the previous version v3.0.2; overall, the page’s scope appears to shift away from detailed drug-safety content.SummaryDifference0.4%

Stay in the know with updates to NYX-2925 Efficacy & Safety in DPN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NYX-2925 Efficacy & Safety in DPN Clinical Trial page.